Lexaria Bioscience hires CRO for GLP-1 human pilot study

Lexaria Bioscience hired a contract research organization to perform the Company’s second DehydraTECH-powered glucagon-like peptide 1 human pilot study #2. The Study will be a randomized, crossover, placebo-controlled investigation that will compare three dose formulations each at a 7 mg semaglutide dose: a positive control Rybelsus swallowed tablet; DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. Semaglutide swallowed into the stomach/intestine absorbs into the bloodstream at an exceptionally low rate typically at less than 1%, when it does not use any absorption technology because, in part, the acidic environment of the stomach is known to seriously degrade GLP-1 drugs. Manufacturing of the test articles for this Study is anticipated to be completed within 30 days. Independent Review Board approval is required before the Study can commence, and the Company will provide our next update when dosing has begun.